PHARMASECURITY

Pharmaceuticals and Security: The Role of Public-Private Collaborations in Strengthening Global Health Security

Coordinatore	UNIVERSITY OF SUSSEX    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	1˙197˙693 €
EC contributo	1˙197˙693 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2012-StG_20111124
Funding Scheme	ERC-SG
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-02-01   -   2018-01-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF SUSSEX  Organization address address: Sussex House city: FALMER, BRIGHTON postcode: BN1 9RH contact info Titolo: Mr. Nome: David Cognome: Rose Email: send email Telefono: +44 1273 876592 Fax: +44 1273 678192	UK (FALMER, BRIGHTON)	hostInstitution	1˙197˙693.80
2	UNIVERSITY OF SUSSEX  Organization address address: Sussex House city: FALMER, BRIGHTON postcode: BN1 9RH contact info Titolo: Prof. Nome: Stefan Cognome: Elbe Email: send email Telefono: 441274000000	UK (FALMER, BRIGHTON)	hostInstitution	1˙197˙693.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Governments in Europe (and beyond) have begun to express grave concern about a number of acute, transnational health threats endangering their citizens and economies. Whether it is the spectre of a future pandemic, the threat of a bioterrorist attack, or the continuing burden of infectious diseases in many developing countries - strengthening the protection against transnational public health threats is increasingly viewed as an urgent matter of international politics. Ongoing efforts by the European Union to develop its own health security strategy will require the formation of effective and sustainable partnerships with numerous stakeholders, including the scientific, medical, and public health communities, as well as private industry – especially in the form of pharmaceutical companies. The latter are particularly crucial actors because of the prominent role that pharmaceutical therapies like vaccines, antivirals, antibiotics, etc. play in strengthening health security. Cooperation with the pharmaceutical industry is therefore necessary to ensure that the required drugs are available in sufficient quantities, in the places where they are needed, and at the right time. Yet very little – if anything – is actually known about the role of pharmaceutical companies in the formulation and implementation of health security policy. This crucial area not only remains under-researcher; it is, in fact, almost entirely un-researched. The core research challenge this project takes up, therefore, is to conduct the first systematic study of the role of pharmaceutical businesses in health security. The aim of the project is both to improve our understanding of the role that pharmaceutical companies play in shaping contemporary health security policy, and to explore how the emerging (but also politically sensitive) partnerships with pharmaceutical companies can be responsibly managed in the years ahead.'